Open Enrollment: How to find a Medicare plan that meets your needs
By Tom Wilbur | October 14, 2020
Medicare’s annual open enrollment period is right around the corner. In fact, beginning October 15 and running through December 7, newly qualified patients and current Medicare beneficiaries may...
Read More
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
By Nicole Longo | October 13, 2020
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today,...
Read More
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
By Guest Contributor | October 12, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. Today, we are pleased to...
Read More
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
By Abigail Lore | October 12, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...
Read More
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
By Richard Moscicki, M.D. | October 8, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, another virus with deadly consequences is right around the corner. The COVID-19 pandemic has led to more than 7.5...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | October 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Growth in 340B program has not translated to improvements for patients
By Nicole Longo | October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....
Read More
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
By Megan Van Etten | October 2, 2020
The first Friday of October marks Manufacturing Day, an annual recognition of the critical role manufacturing industries play in powering innovation and generating jobs and economic growth for...
Read More
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
By Stephen J. Ubl | October 1, 2020
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Read More
Three reasons why repealing the Part D non-interference clause is a bad idea
By Tom Wilbur | October 1, 2020
For more than a decade, Medicare Part D has provided seniors affordable and comprehensive prescription drug coverage. Its unique, market-based structure has kept overall Part D program costs far...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
